Innovent Biologics is Drug Discovery in China that focus on oncology therapeutics business. Founded in 2011. They cover business area such as innovent, drug, disease, especially oncology therapeutic, approval, its first core asset, Tyvyt, sinitilimab, its other three product, biosimilar version, bevacizumab, rituximab, adalimumab, Byvasda, Halpryza, Sulinno, adept global business development, Eli Lilly, several partner.
2011
( 13 years old in 2024 )
Oncology Therapeutics
-
168 Dongping Street
Suzhou Industrial Park
Suzhou, Jiangsu 215123
China
Private
innoventdrugdiseaseespecially oncology therapeuticapprovalits first core assetTyvytsinitilimabits other three productbiosimilar versionbevacizumabrituximabadalimumabByvasdaHalpryzaSulinnoadept global business developmentEli Lillyseveral partner
* We use standard office opening hours in near Innovent Biologics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Innovent Biologics is Drug Discovery business from China that founded in 2011 (13 years old in 2024), Innovent Biologics business is focusing on Oncology Therapeutics.
Innovent Biologics headquarter office and corporate office address is located in 168 Dongping Street Suzhou Industrial Park Suzhou, Jiangsu 215123 China.
Innovent Biologics was founded in China.
In 2024, Innovent Biologics is currently focus on oncology therapeutics sector.
Above is snippet of Google Trends for "oncology therapeutics" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Innovent Biologics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
